 |
| Editors' Choice: Story of the Week | |
 |
Commentary
2009 Oct 28, Lee Schwartzberg, MD, PhD, Editor-in-Chief
Paclitaxel is a schedule-dependent chemotherapeutic agent. This phase III trial in advanced ovarian cancer confirms this finding in yet another disease setting, showing that standard carboplatin plus continuous weekly paclitaxel at 80 mg/m2 results in a PFS and an OS advantage. While the weekly paclitaxel regimen used in this study was not strictly dose dense according to the conventional definition of a standard dose given more frequently, it did result in a higher total dose intensity per cycle. It would thus appear that weekly paclitaxel dosing should be adopted as the standard of care in ovarian cancer.
|
Weekly Paclitaxel Plus Carboplatin Demonstrates Survival Benefit in Advanced Ovarian Cancer 
Lancet, 2009 Sept 18, N Katsumata, et al
EXPERT COMMENTARY
Phase III study shows "dose-dense" weekly paclitaxel plus carboplatin every 3 weeks improved 3-year OS vs the conventional regimen.
|
| Editors' Page | |
|
Proposed Payment Reductions Squeeze Oncologists
2009 Oct 28, Lee Schwartzberg, MD, PhD, Editor-in-Chief
Congress is now debating 3 independent, but related, physician payment initiatives, and the stakes for oncology are high.
|
| News | More » |
|
Cancer Screening Critique Causes Media Firestorm
Elsevier Global Medical News, 2009 Oct 22, S Boschert
A New York Times report that ACS plans to temper its proscreening message for breast and prostate cancers creates controversy over the benefits of screening.
|
Comparable Results From Three Forms of Accelerated Partial-Breast Irradiation
Elsevier Global Medical News, 2009 Oct 21, S Boschert
A comparison in 373 patients found comparable rates of local control, survival, and acceptable cosmesis over a median 6 years of follow-up.
|
CHEK2 Mutation Increases Mortality, Breast Cancer Recurrences
Elsevier Global Medical News, 2009 Oct 21, S Boschert
White breast cancer patients of European descent with a CHEK2 mutation are 40% more likely to die of breast cancer or any cause within 10 years.
|
Cardiovascular Risk May Be Greater Than Breast Cancer Recurrence Risk in Some Patients
Elsevier Global Medical News, 2009 Oct 19, S Boschert
Estimated 10-year risk for CV disease was at least as great as breast cancer recurrence risk among postmenopausal women treated with an AI.
|
| Journal Scans | More » |
|
Dose-Escalated Image-Guided Radiotherapy for Spinal Metastases
Int J Radiat Oncol Biol Phys, 2009 Nov 1, M Guckenberger, et al
Dose-escalated irradiation was safe and achieved excellent local control of spinal metastases and paraspinal tumors.
|
Clinical Features and Outcomes in Adult T-Cell ALL
Blood, 2009 Oct 14, DI Marks, et al
Large, prospective, randomized trial delineates clinical and molecular features and outcome in adults with T-lineage ALL.
|
Efficacy of PEG-IFN-Alfa-2a in Essential Thrombocythemia and Polycythemia Vera
J Clin Oncol, 2009 Oct 13, A Quintás-Cardama , et al
Phase II trial of PEG-IFN-alfa-2a shows impressive hematologic and molecular response rates in pretreated patients with ET and PV.
|
| What Patients Are Reading | More » |
|
Where to Go for Cancer Care—A Shot in the Dark
As Reported by Newsweek, 2009 Oct 26
Finding good cancer care can be daunting, and statistics show that outcomes for some cancers are better at elite hospitals.
|
Medical Imaging Boosts Levels of Radiation Exposure
As Reported by HealthDay News, 2009 Oct 27
Largely unregulated, the use of medical imaging is now the primary source of radiation exposure in America.
|
Suicidal Thoughts Occur in Adult Survivors of Childhood Cancer
As Reported by Reuters, 2009 Oct 23
Suicidal thoughts occurred 11 years after childhood cancer and were more prevalent among survivors who were in poor health.
|
High-Fat Diet Detrimental for Patients With a Prior History of Skin Cancer
As Reported by Reuters, 2009 Oct 23
A second squamous cell skin cancer was more likely if patients with a prior history consumed a high-fat diet.
|
|
| | |
| EDITORIAL BOARD
Our physician editors collaborate weekly to choose the website's top story.
VISIT SITE
| |
|
|
| | |
| ASCO BREAST
Read conference news from this year's multidisciplinary event.
| |
|
|
| | |
| ECCO/ESMO 2009
Conference news plus interviews with ECCO/ESMO officers.
| |
|
|
| | |
| MM CME
Earn valuable credits by participating in this case-based online program in multiple myeloma.
| |
|
|
| | |
| COMMENTARY
Dr. David Henry focuses on some of the studies presented at ECCO/ESMO that may change or influence practice.
VISIT SITE
| |
|
|
| | |
| PRACTICE MANAGEMENT
Key information on everything from legal affairs to new technologies.
VISIT SITE
| |
|
|
|
The Latest Oncology Intelligence
